CD274 and nasopharyngeal carcinoma: Amidst the positive clinical trial results of anti-PD-1 immunotherapy in NPC with 20–34% overall response rates, it would be important to determine if PD-L1 genomic aberrations can predict outcomes for PD-1/PD-L1 targeting in clinical settings34–36.